로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > 전시회 > Advancing Drug Development and Disease Modeling with Human iPSC-derived Organoids
  1. Advancing Drug Development and Disease Modeling with Human iPSC-derived Organoids

    1. 17:00 CET, 22nd May
    2. Online
    3. Idil Ariöz, M.Sc., Field Application Scientist, Neuroscience & Organoid
    Click the button to enter our raffle.
  2. At ACROBiosystems, Idil Ariöz has played a crucial role in providing support and guidance to customers, as well as developing promotion and co-marketing strategies by analyzing industry pain-points. Before joining ACROBiosystems, Idil conducted academic scientific research in various fields of neuroscience during her master's and doctoral studies. Her research focused on topics such as neural regeneration, spatial distribution of synaptic proteins at the nano-scale, and molecular targets in epileptogenic neurodevelopmental diseases.


    In snapshot:

    · Organoids represent promising advancements in translatable disease modeling and overcoming the high preclinical drug failure rate.

    · ACROBiosystems offers hydrogel-free human iPSC-derived organoids, which are miniature organs composed of multiple cell types. These organoids include inherent vascular and immune components and have been verified through multi-modal functional and structural tests. The available organoid types are:

    -  Cardiac organoids

    -  Cerebral organoids

    -  Liver organoids

    -  Intestinal organoids


    · These organoids have been used to create disease models of Alzheimer’s Disease, Parkinsons’s Disease, Nonalcoholic Fatty Liver Disease (NASH), Inflammatory Bowel Disease (IBD), acute toxicity, neuroinflammation and have been used as AAV gene delivery models.

    · ACROBiosystems hiPSC-derived organoids may be promising improved preclinical models for drug development, safety assessment and diseases models to help provide better guidance when moving into clinical research.


    Organoids are miniature organs with the representative functionality and structure of the organ. Current organoid technologies usually lack certain physiological cell types, translatable biological assays, even though they are a promising advancement in drug development and disease modeling to combat high clinical drug failure rates, even after rigorous preclinical testing. As ACROBiosystems, we have developed novel commercially available hydrogel-free human iPSC-derived cardiac, cerebral, liver and intestinal organoid systems, with high throughput capabilities. These models have a human genetic background, bear several cell types of the organ that they model and have inherent vascular and immune components, verified by immunofluorescence marker assay and transcriptomics. The functionality of the organoids have been verified by patch-clamp, multi-electrode assay (MEA), silicon probe recordings, in the case for electrically active organ models; cardiac and cerebral organoids. Liver organoids have been functionally validated through the expression of albumin, CYP450 enzymes, and BSEP. Similarly, intestinal organoids have been confirmed based on their ability to absorb nutrients.. Moreover, these organoids have been used to create disease models of Alzheimer’s disease, Parkinsons’s disease, Nonalcoholic Fatty Liver Disease (NASH), Inflammatory Bowel Disease (IBD), acute toxicity, neuroinflammation and have been used as adeno-associated virus (AAV) mediated gene delivery models. We outline the use of ACROBiosystems hiPSC-derived organoids as an improved preclinical model for drug development, safety assessment and diseases models to help provide better guidance when moving into clinical research.


    Watch the Webinar on Demand!




New & Hot Products


This web search service is supported by Google Inc.

totop